

Provided by:



## Melanoma and Cutaneous Malignancy Tumor Board 2025-2026

**Melanoma and Cutaneous Malignancy Tumor Board 2025-2026 - 7/22/2026**

**July 22, 2026**

**12:00 PM - 1:00 PM**

**PCAM South Tower Room 10-124**

### **Target Audience**

This program has been designed for DERMATOLOGY, DIAGNOSTIC RADIOLOGY, INTERNAL MEDICINE - Medical Oncology, PLASTIC SURGERY, RADIATION ONCOLOGY, OTOLARYNGOLOGY, DERMATOLOGY - Dermatopathology, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology, OBSTETRICS AND GYNECOLOGY - Gynecologic Oncology, PATHOLOGY - Dermatopathology, SURGERY - Complex General Surgical Oncology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss a multidisciplinary approach to care for patients with melanoma and other cutaneous malignancies.
- 2 Describe how to accurately diagnose, stage, and develop appropriate treatment plans for patients with melanoma and other cutaneous malignancies.
- 3 Discuss treatment plans for patients with melanoma and other cutaneous malignancies using proven standardized methods and consider open investigative clinical trials.
- 4 Describe how to treat patients in a holistic view considering social, psychological, spiritual, and financial barriers.

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact  
Ahron Flowers, Samia White  
(215) 360-0911, (215) 662-3002

[aflow@penntmedicine.upenn.edu](mailto:aflow@penntmedicine.upenn.edu), [Samia.White@Penntmedicine.upenn.edu](mailto:Samia.White@Penntmedicine.upenn.edu)

**Check your transcript online at <https://upenn.cloud-cme.com>**

**Designation of Credit:**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**ABS CC:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

**ABPath MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours.

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\*:** None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Ravi Amaravadi, MD	Other Planning Committee Member	Ownership-Pinpoint Thrapeutics (Relationship has ended)   Advisor-Tasca   Grant or research support-Deciphera   Grant or research support-Springworks   Grant or research support-Merck & Co   Grant or research support-Bristol-Myers Squibb   Grant or research support-Pinpoint Therapeutics (Relationship has ended)   Advisor-Immunacell (Relationship has ended) - 08/07/2025
Emily Chu, MD	Other Planning Committee Member	Nothing to disclose - 03/10/2026
David E Elder, MBBS	Other Planning Committee Member	Nothing to disclose - 08/07/2025
Rosalie Elenitsas, MD	Other Planning Committee Member	Nothing to disclose - 06/08/2026
Michael Farwell, MD	Other Planning Committee Member	Grant or research support-ImaginAb   Grant or research support-Carisma (Relationship has ended)   Consulting Fee-Abcuro - 11/10/2025
Giorgos Karakousis, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 06/08/2026
Kristin Kreider, PA-C	Physician Assistant Planner	Nothing to disclose - 01/27/2026
John N Lukens, MD	Other Planning Committee Member	Nothing to disclose - 11/24/2025
Russell Maxwell, MD	Other Planning Committee Member	Nothing to disclose - 10/28/2025

Suzanne Start here McGettigan, CRNP RN	Nurse Planner	Speakers Bureau-Bristol-Myers Squibb Consulting Fee-Merck & Co Speakers Bureau-Regeneron Pharmaceuticals, Inc. - 06/08/2026
Tara C mitchell, MD	Co-Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Merck & Co Membership on Advisory Committees or Review Panels, Board Membership, etc.-Tempus Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb - 12/19/2025
John Miura, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 08/19/2025
Meghan Mulligan, CRNP	Nurse Planner	Nothing to disclose - 10/30/2025
Lynn M Schuchter, MD	Course Director, Faculty	Nothing to disclose - 08/22/2025
Joanna L Walker, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- SunPharma - 06/04/2026
Xu Xiaowei, MD	Other Planning Committee Member	Grant or research support-Incyte Corporation (Relationship has ended) Advisor-Society for Immunotherapy of Cancer (Relationship has ended) - 04/21/2026

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected